



Hannah Joseph Hospital

(Institute of Neurosciences & Trauma)

(Please Scan this QR Code to view the Prospectus)

Registered Office: 134, Lake View Road K.K.Nagar, Madurai, Tamil Nadu, India, 625020. Corporate Office: Hannah Joseph Hospital RS 115-352, Madurai-Tuticorin Ring Road, Chintamani, Madurai, Madurai North, Tamil Nadu, India, 625009. Mob. No.: 9524729594; Contact Person: Yuvaraj Saravanan, Company Secretary & Compliance Officer E-mail id: cs@hannahjosephhospital.com; Website: <https://hannahjosephhospital.com/>; CIN: U74999TN2011PLC082860

PROMOTERS OF OUR COMPANY: Moses Joseph Arunkumar, Fenn Kavitha Fenn Arunkumar, Arunkumar Nalina and Noyel Arunkumar

OUR COMPANY HAS FILED THE PROSPECTUS DATED JANUARY 29, 2026, WITH THE ROC ON THURSDAY, JANUARY 29, 2026, AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON SME PLATFORM OF BSE LIMITED ("BSE SME" OR "STOCK EXCHANGE") AND THE TRADING IS EXPECTED TO COMMENCE ON MONDAY, FEBRUARY 02, 2026.

BASIS OF ALLOTMENT

INITIAL PUBLIC ISSUE OF UP TO 60,00,000 EQUITY SHARES OF FACE VALUE OF ₹10/- EACH ("EQUITY SHARES") OF HANNAH JOSEPH HOSPITAL LIMITED ("COMPANY" / "ISSUER") FOR CASH AT A PRICE OF ₹70/- PER EQUITY SHARE (INCLUDING A SHARE PREMIUM OF ₹60/- PER EQUITY SHARE) ("ISSUE PRICE") AGGREGATING UP TO ₹4,200 LAKHS ("ISSUE"), OF WHICH 3,00,000 EQUITY SHARES OF FACE VALUE OF ₹10/- EACH FOR CASH AT A PRICE OF ₹70/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹60/- PER EQUITY SHARE AGGREGATING TO ₹210 LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER TO THE ISSUE (THE "MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION i.e. NET ISSUE OF 57,00,000 EQUITY SHARES OF FACE VALUE OF ₹10/- EACH AT A PRICE OF ₹70/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹60/- PER EQUITY SHARE AGGREGATING ₹3,990 LAKHS IS HEREIN AFTER REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 26.43% AND 25.11%, RESPECTIVELY, OF THE POST ISSUE PAID UP EQUITY SHARE CAPITAL OF OUR COMPANY.

THE FACE VALUE OF THE EQUITY SHARES IS ₹10/- EACH

ANCHOR INVESTOR ISSUE PRICE IS ₹70 PER EQUITY SHARE

THE ISSUE PRICE IS ₹70 PER EQUITY SHARE

THE ISSUE PRICE IS 7 TIMES OF THE FACE VALUE OF THE EQUITY SHARES

RISKS TO INVESTORS

For details refer to section titled "Risk Factor" beginning on page 26 of the Prospectus.

1. Risk to Investors: Summary description of key risk factors based on materiality.

- We intend to utilize a portion of the Net Proceeds for setting up the Proposed Radiation Oncology Centre adjacent to the current hospital campus. We are yet to place orders for medical equipments and apply for requisite government approvals for the Proposed Radiation Oncology Centre. If we are unable to commission our Proposed Radiation Oncology Centre without time and cost overruns or unable to adhere to the schedule of implementation, it may adversely affect our business, results of operations and financial conditions.
- We are required to obtain statutory and regulatory approvals, licenses or permits for our proposed radiation oncology centre. If we fail to obtain, maintain or renew our statutory and regulatory approvals or permits, our business, results of operations, financial condition, and cash flows could be adversely affected.
- There are outstanding legal proceedings involving our Company. Any adverse decisions could impact our net worth, profitability, cashflows and divert management time and attention and have an adverse effect on our business, prospects, results of operations and financial condition.
- Our Company did not open a separate bank account for private placements made in the past, utilized the proceeds from the issuance prior filing of Form PAS-3, and issued private placement offer cum application letter before filing the Form MGT-14 with registrar and determined the relevant date within 30 days prior to the date of general meeting in violation of Section 42 of the Companies Act, 2013 and the rules made thereunder, which may have a material adverse effect on our business.
- While generating the UDIN for the Re-audited financial statements for FY 2023-24, the 'Certificate' category was selected due to unavailability of a specific 'Re-audit' or 'Restatement' option on the ICAI UDIN portal, which may be viewed as a procedural irregularity.

Details of suitable ratios of the Company for the latest full financial year ended March 31, 2025:

1. Basic and Diluted Earnings Per Share (EPS):

Sr. No.	Financial Year/Period	Basic & Diluted EPS (in ₹)	Weights	EPS x Weight
1	Financial Year ended March 31, 2025	4.32	3	12.96
2	Financial Year ended March 31, 2024	2.47	2	4.94
3	Financial Year ended March 31, 2023	0.63	1	0.63
	Weighted Average			3.09
	Total			6
	Period ended September 30, 2025*			18.53

*Not Annualized

Notes:

1. The figures disclosed above are based on the Restated Financial Statements of the Company.

2. The face value of each Equity Share is ₹ 10.00.

3. Weighted average = Aggregate of year-wise weighted EPS divided by the aggregate of weights i.e. sum of (EPS x Weight) for each year/Total of weights.

4. Earnings per Share has been calculated in accordance with Indian Accounting Standard 33 – "Earnings per Share".

2. Price to Earnings (P/E) ratio in relation to Price Band of ₹67 and ₹70 per Equity Shares

Particulars	EPS (in ₹)	P/E Ratio at the Floor Price (No. of times)	P/E Ratio at the Cap Price (No. of times)
P/E ratio based on the Basic & Diluted EPS, as restated for FY 2024-25	4.32	15.51	16.20
P/E ratio based on the Weighted Average EPS, as restated	3.09	21.68	22.65

BID / ISSUE PROGRAMME

ANCHOR INVESTOR BIDDING DATE OPENED AND CLOSED ON: WEDNESDAY, JANUARY 21, 2026

BID / ISSUE OPENED ON: THURSDAY, JANUARY 22, 2026 | BID / ISSUE CLOSED ON WEDNESDAY, JANUARY 28, 2026

PROPOSED LISTING: MONDAY, FEBRUARY 02, 2026*

*Subject to the receipt of listing and trading approval from the BSE.

The issue is being made through the Book Building Process, in terms of Rule 19(2)(b)(ii) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 253 of the SEBI ICDR Regulations, as amended, wherein not more than 50% of the Net Issue shall be allocated on a proportionate basis to Qualified Institutional Buyers ("QIBs") (the "QIB Portion"), provided that our Company may, in consultation with the Book Running Lead Managers, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), out of which 33.33% of the Anchor Investor Portion shall be reserved for domestic Mutual Funds and 6.67% for life insurance companies and pension funds, subject to valid bids being received from domestic Mutual Funds, life insurance companies and pension funds at or above the Anchor Investor Allocation Price, in accordance with the SEBI ICDR Regulations. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion. Further, 5% of the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining Net QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Net Issue shall be available for allocation on a proportionate basis to Non-Institutional Bidders of which (a) one-third of portion shall be reserved for applicants with application size of more than two lots and up to ₹10,00,000, and (b) two-third of such portion shall be reserved for applicants with application size of more than ₹10,00,000, provided that the unsubscribed portion in either of such sub-categories may be allocated to applicants in the other sub-category of Non-Institutional Bidders, in accordance with the SEBI ICDR Regulations, subject to valid bids being received at or above the Issue Price and not less than 35% of the Net Issue shall be available for allocation to Individual Bidders who applies for minimum application size in accordance with the SEBI ICDR Regulations, subject to valid bids being received at or above the Issue Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilise the Application Supported by Blocked Amount ("ASBA") process by providing details of their respective bank accounts (including UPI ID for UPI Bidder using the UPI Mechanism) (defined hereinafter), in which the corresponding Bid Amounts will be blocked by the Self Certified Syndicate Banks ("SCSBs") or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the issue through the ASBA process. For details, see "Issue Procedure" beginning on page no. 256 of the Prospectus.

SUBSCRIPTION DETAILS

The bidding for Anchor Investors opened and closed on January 21, 2026. The Company received 7 Anchor Investors applications for 2290500 Equity Shares against 1706000 Equity Shares reserved for Anchor Investors. The Anchor Investor Allocation price was finalized at ₹70 per Equity Share. A total of 1706000 Equity Shares were allotted under the Anchor Investor portion aggregating to ₹19420000/-.

The issue (including Anchor Investors Portion) received 887 Applications for 8666500 Equity Shares (prior to rejections) resulting in 1.35 times subscription (including reserved portion of market maker). The details of the Applications received in the issue from various categories are as under:

Detail of the Applications Received from various categories including market maker are as under:

Sr. No.	Category	No. of Applications received	No. of Equity Shares applied	No. of Equity Shares reserved as per Prospectus	No. of times Subscribed	Amount (₹)
1	Qualified Institutional Bidders (excluding Anchor Investors)	5	1230000	1140000	1.08	8610000
2	Non-Institutional Investors - More than 2 Lakhs Upto 10 Lakhs	53	370000	286000	1.29	2590000
3	Non-Institutional Investors - Above 10 Lakhs	35	1332000	572000	2.33	9324000
4	Individual Investors	786	3144000	1996000	1.58	22008000
5	Anchor Investors	7	2290500	1706000	1.34	16033500
6	Market Maker	1	300000	300000	1.00	2100000
Total		887	8666500	6000000	1.35	60665500

Final Demand:

A summary of final demand (prior to any rejections) as per BSE as on the Bid/Issue Closing Date at different prices is as under:

Sr. No.	Bid Price	No. of Equity Shares	% to Total	Cumulative Share Total	Cumulative % of Total
1	67.00	296000	1.63	296000	1.63
2	68.00	142000	0.78	438000	2.41
3	69.00	56000	0.31	494000	2.72
4	70.00	1766000	97.28	18154000	100.00
Total		18154000			

The basis of allotment was finalized in consultation with the Designated Stock Exchange, being BSE Limited (BSE SME) on January 29, 2026.

a) Allotment to Individual Investors (After Rejections & Withdrawal):

The Basis of Allotment to the Individual Investors, who have Bid at cut-off Price or at or above the Issue Price of ₹70/- per Equity Share, was finalized in consultation with BSE SME.

The category was subscribed by 1.58 times i.e., for 3144000 Equity Shares. The total number of Equity Shares allotted in this category is 1996000 Equity Shares to 499 successful applicants.

The category wise details of the Basis of Allotment are as under:

Sr. No.	No. of Shares applied for (Category wise)	Number of applications received	% to total	Total No. of Shares applied in each	% to total	Allocation per Applicant	Ratio of allottees to applicants	Number of successful applicants (after rounding)	% to total	Total No. of shares allocated/ allotted	% to total	Surplus/ Deficit (14)-(7)	
1	4000	786	100	3144000	100	2539.44	4000	499	786	499	100	1996000	100

b) Allotment to Non-Institutional Investors (More than Rs. 2 lakhs Up to Rs. 10 lakhs) (After Technical Rejections & Withdrawal):